Cancer Res Treat.  2015 Oct;47(4):757-764. 10.4143/crt.2014.039.

Using the Lymph Node Ratio to Evaluate the Prognosis of Stage II/III Breast Cancer Patients Who Received Neoadjuvant Chemotherapy and Mastectomy

• Wu SG
• Li Q
• Zhou J
• Sun JY
• Li FY
• Lin Q
• Lin HX
• Gaun XX
• He ZY

• KMID: 2403394
• DOI: http://doi.org/10.4143/crt.2014.039

Abstract

PURPOSE
This study was conducted to investigate the prognostic value of lymph node ratio (LNR) in stage II/III breast cancer patients who undergo mastectomy after neoadjuvant chemotherapy.
MATERIALS AND METHODS
Clinical and pathological data describing stage II/III breast cancer patients were included in this retrospective study. The primary outcomes were locoregional recurrence-free survival (LRFS), distant metastasis-free survival (DMFS), disease-free survival (DFS), and overall survival (OS).
RESULTS
Among 277 patients, there were 43 ypN0, 64 ypN1, 89 ypN2, and 81 ypN3 cases. Additionally, there were 43, 57, 92 and 85 cases in the LNR 0, 0.01-0.20, 0.21-0.65, and > 0.65 groups, respectively. The median follow-up was 49.5 months. Univariate analysis showed that both ypN stage and LNR were prognostic factors of LRFS, DMFS, DFS, and OS (p < 0.05). Multivariate analysis showed that LNR was an independent prognostic factor of LRFS, DMFS, DFS, and OS (p < 0.05), while ypN stage had no effect on prognosis (p > 0.05).
CONCLUSION
The integrated use of LNR and ypN may be suitable for evaluation the prognosis of stage II/III breast cancer patients who undergo mastectomy after neoadjuvant chemotherapy.

Keyword

Breast neoplasms; Mastectomy; Neoadjuvant therapy; Lymph nodes; Prognosis

MeSH Terms

Breast Neoplasms*
Breast*
Disease-Free Survival
Drug Therapy*
Follow-Up Studies
Humans
Lymph Nodes*
Mastectomy*
Multivariate Analysis
Neoadjuvant Therapy
Prognosis*
Retrospective Studies

Figure

• 

  Fig. 1. Comparison of Kaplan-Meier curves for different lymph node ratios (LNRs) and ypN stages. (A, E) Locoregional recurrence-free survival. (B, F) Distant metastasis-free survival. (C, G) Disease-free survival. (D, H) Overall survival. pN (A-D) and LNR (E-H).

Reference

References

1. Mauri D, Pavlidis N, Ioannidis JP. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst. 2005; 97:188–94.

2. Kaufmann M, von Minckwitz G, Smith R, Valero V, Gianni L, Eiermann W, et al. International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations. J Clin Oncol. 2003; 21:2600–8.

3. Estevez LG, Gradishar WJ. Evidence-based use of neoadjuvant taxane in operable and inoperable breast cancer. Clin Cancer Res. 2004; 10:3249–61.

4. Shimizu C, Ando M, Kouno T, Katsumata N, Fujiwara Y. Current trends and controversies over pre-operative chemotherapy for women with operable breast cancer. Jpn J Clin Oncol. 2007; 37:1–8.

5. Keam B, Im SA, Kim HJ, Oh DY, Kim JH, Lee SH, et al. Clinical significance of axillary nodal ratio in stage II/III breast cancer treated with neoadjuvant chemotherapy. Breast Cancer Res Treat. 2009; 116:153–60.

6. Fisher B, Brown A, Mamounas E, Wieand S, Robidoux A, Margolese RG, et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol. 1997; 15:2483–93.

7. Baslaim MM, Al Malik OA, Al-Sobhi SS, Ibrahim E, Ezzat A, Ajarim D, et al. Decreased axillary lymph node retrieval in patients after neoadjuvant chemotherapy. Am J Surg. 2002; 184:299–301.

8. Belanger J, Soucy G, Sideris L, Leblanc G, Drolet P, Mitchell A, et al. Neoadjuvant chemotherapy in invasive breast cancer results in a lower axillary lymph node count. J Am Coll Surg. 2008; 206:704–8.

9. Neuman H, Carey LA, Ollila DW, Livasy C, Calvo BF, Meyer AA, et al. Axillary lymph node count is lower after neoadjuvant chemotherapy. Am J Surg. 2006; 191:827–9.

10. Vinh-Hung V, Verkooijen HM, Fioretta G, Neyroud-Caspar I, Rapiti E, Vlastos G, et al. Lymph node ratio as an alternative to pN staging in node-positive breast cancer. J Clin Oncol. 2009; 27:1062–8.

11. Danko ME, Bennett KM, Zhai J, Marks JR, Olson JA Jr. Improved staging in node-positive breast cancer patients using lymph node ratio: results in 1,788 patients with long-term follow-up. J Am Coll Surg. 2010; 210:797–805.

12. Chagpar AB, Camp RL, Rimm DL. Lymph node ratio should be considered for incorporation into staging for breast cancer. Ann Surg Oncol. 2011; 18:3143–8.

13. Ahn SH, Kim HJ, Lee JW, Gong GY, Noh DY, Yang JH, et al. Lymph node ratio and pN staging in patients with node-positive breast cancer: a report from the Korean breast cancer society. Breast Cancer Res Treat. 2011; 130:507–15.

14. Wu SG, Chen Y, Sun JY, Li FY, Lin Q, Lin HX, et al. Using the lymph nodal ratio to predict the risk of locoregional recurrence in lymph node-positive breast cancer patients treated with mastectomy without radiation therapy. Radiat Oncol. 2013; 8:119.

15. Wu SG, He ZY, Li Q, Sun JY, Li FY, Lin Q, et al. Prognostic value of metastatic axillary lymph node ratio for Chinese breast cancer patients. PLoS One. 2013; 8:e61410.

16. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ, et al. Strategies for subtypes: dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol. 2011; 22:1736–47.

17. Houssami N, Macaskill P, von Minckwitz G, Marinovich ML, Mamounas E. Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy. Eur J Cancer. 2012; 48:3342–54.

18. Saxena N, Hartman M, Aziz R, Rapiti E, Bhoo Pathy N, Lim SE, et al. Prognostic value of axillary lymph node status after neoadjuvant chemotherapy: Results from a multicentre study. Eur J Cancer. 2011; 47:1186–92.

19. Jeruss JS, Mittendorf EA, Tucker SL, Gonzalez-Angulo AM, Buchholz TA, Sahin AA, et al. Staging of breast cancer in the neoadjuvant setting. Cancer Res. 2008; 68:6477–81.

20. Veronesi U, Zurrida S, Viale G, Galimberti V, Arnone P, Nole F. Rethinking TNM: a breast cancer classification to guide to treatment and facilitate research. Breast J. 2009; 15:291–5.

21. Truong PT, Woodward WA, Thames HD, Ragaz J, Olivotto IA, Buchholz TA. The ratio of positive to excised nodes identifies high-risk subsets and reduces inter-institutional differences in locoregional recurrence risk estimates in breast cancer patients with 1-3 positive nodes: an analysis of prospective data from British Columbia and the M. D. Anderson Cancer Center. Int J Radiat Oncol Biol Phys. 2007; 68:59–65.

22. Castrucci W, Lannin D, Haffty BG, Higgins SA, Moran MS. Using nodal ratios to predict risk of regional recurrences in patients treated with breast conservation therapy with 4 or more positive lymph nodes. ISRN Surg. 2011; 2011:874814.

23. Vinh-Hung V, Nguyen NP, Cserni G, Truong P, Woodward W, Verkooijen HM, et al. Prognostic value of nodal ratios in node-positive breast cancer: a compiled update. Future Oncol. 2009; 5:1585–603.

24. Woodward WA, Vinh-Hung V, Ueno NT, Cheng YC, Royce M, Tai P, et al. Prognostic value of nodal ratios in node-positive breast cancer. J Clin Oncol. 2006; 24:2910–6.